Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > KLY

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Jun 09, 2020 8:41am

78 Views

Post# 31127788

RE:KLY

Bawker wrote:
"extraordinary improvement was sustained for the full period of four hours of observation after dosing. Treatment with R-107 was not associated with apparent side effects:"

"These preclinical findings are significantly superior in both their potency and duration of activity compared to results of currently marketed agents evaluated in the same animal models of PAH. “There are currently no approved treatments for PAH caused by the COVID-19 virus, which is in fact a severe form of ARDS."

... I like it .... I like it .... I like it!!

<< Previous

Bullboard Posts

Next >>

Canadian rare earths stock up as drilling starts at uranium property